We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Cisco, Lam, Thermo Fisher Scientific, Ampco-Pittsburgh and Catalyst
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 17 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cisco Systems, Inc. (CSCO - Free Report) , Lam Research Corp. (LRCX - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , Ampco-Pittsburgh Corp. (AP - Free Report) and Catalyst Bancorp, Inc. (CLST - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Cisco, Lam Research and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc., Lam Research Corp. and Thermo Fisher Scientific Inc., as well as two micro-cap stocks Ampco-Pittsburgh Corp. and Catalyst Bancorp, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Cisco’s shares have outperformed the Zacks Computer - Networking industry over the past year (+65.9% vs. +64.3%). The company’s prospects are benefiting from broad demand across networking, security and collaboration. AI infrastructure orders, integrated silicon and an end-of-support refresh opportunity support a multi-year networking cycle, while newer security products and Splunk’s recovery broaden the growth base.
Cisco also retains operating leverage and continues to return cash to shareholders. Offsetting these positives, a hardware-led revenue mix is expected to limit gross-margin expansion, while services recovery should remain gradual.
Competition across networking and security still requires sustained product execution. Acquisition exposure and an elevated valuation leave less room for disappointment. The balanced mix of durable growth drivers and execution, margin and valuation risks supports the Neutral recommendation.
Shares of Lam Research have outperformed the Zacks Electronics - Semiconductors industry over the past year (+123.1% vs. +27.4%). The company is benefiting from AI-driven investment in memory, leading-edge foundry and advanced packaging. Rising process complexity is increasing demand for etch and deposition tools, while NAND conversions, advanced DRAM and larger packages expand its served market.
Customer Support is scaling through upgrades, high utilization and early adoption of Equipment Intelligence and Dextro services. Record fiscal 2026 results, higher margin targets and a sizable September-quarter outlook reinforce execution. Cash generation and capital returns add support.
However, equipment spending remains cyclical, China exposure is volatile, and export controls can disrupt demand. Competition, capacity limits and international exposure also remain risks. Overall, structural AI demand and rising technology content support the Outperform view.
Thermo Fisher’s shares have outperformed the Zacks Medical - Instruments industry over the past year (+36.2% vs. -0.5%). The company is gaining from improving customer activity across all end markets, continued share gains and disciplined execution of its growth strategy. Pharma and biotech demand is advancing, led by bioproduction, clinical research and the research and safety channel.
Clario and the filtration and separation business are bolstering the company’s capabilities and supporting revenue synergies. New products, AI-enabled workflows and expanded customer collaboration centers reinforce its competitive position.
Management raised its 2026 revenue and adjusted EPS outlook after better-than-expected second-quarter results. The Zacks Consensus Estimate projects 2026 EPS of $25.12 on revenues of $47.80 billion. Still, macroeconomic uncertainty, currency volatility, acquisition-related leverage and intense competition remain key risks.
Shares of Ampco-Pittsburgh have outperformed the Zacks Metal Products - Procurement and Fabrication industry over the past year (+211.6% vs. +5.9%). This microcap company with a market capitalization of $160.93 million sees its outlook supported by ALP’s exposure to nuclear power, defense, power generation and mission-critical HVAC, alongside improving FCEP profitability after footprint optimization.
Stronger backlog, protective tariffs, improving FEP activity and better utilization in Sweden provide support for longer-term earnings and margin expansion. However, execution remains important as FCEP is exposed to steel-market cyclicality, product mix and utilization trends, while ALP must convert a growing backlog as capacity expands.
Elevated leverage, weak cash conversion, working-capital needs and asbestos obligations constrain financial flexibility. Residual U.K. recovery uncertainty also remains a risk. Valuation suggests limited near-term upside, making sustained earnings growth, margin expansion and deleveraging important catalysts for improving investor returns.
Catalyst Bancorp’s shares have outperformed the Zacks Banks - Southeast industry over the past year (+36.2% vs. +10.9%). This microcap company with a market capitalization of $72.29 million, with its July 2026 Lakeside acquisition more than doubling its asset, loan and deposit base, is creating a larger franchise with greater earnings potential if the November systems conversion proceeds smoothly.
Funding trends are constructive, with deposits up 6% in the first half, lower deposit costs and a loan-to-deposit ratio of 82.9%. Credit quality also improved, as non-performing and past-due loans declined, supporting provision reversals. Net interest income rose 6.3% in the first half, aided by stronger securities income and growth in selected commercial categories.
However, challenges include 12.1% growth in non-interest expenses, a weaker efficiency ratio and a 4.4% decline in organic loans. Margin compression and heavy real estate exposure also raise sensitivity to funding costs and property-market conditions. Shares trade at 32.58X price/earnings, above peers
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Cisco, Lam, Thermo Fisher Scientific, Ampco-Pittsburgh and Catalyst
For Immediate Release
Chicago, IL – September 17 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cisco Systems, Inc. (CSCO - Free Report) , Lam Research Corp. (LRCX - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , Ampco-Pittsburgh Corp. (AP - Free Report) and Catalyst Bancorp, Inc. (CLST - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Cisco, Lam Research and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc., Lam Research Corp. and Thermo Fisher Scientific Inc., as well as two micro-cap stocks Ampco-Pittsburgh Corp. and Catalyst Bancorp, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Today's Featured Research Reports
Cisco’s shares have outperformed the Zacks Computer - Networking industry over the past year (+65.9% vs. +64.3%). The company’s prospects are benefiting from broad demand across networking, security and collaboration. AI infrastructure orders, integrated silicon and an end-of-support refresh opportunity support a multi-year networking cycle, while newer security products and Splunk’s recovery broaden the growth base.
Cisco also retains operating leverage and continues to return cash to shareholders. Offsetting these positives, a hardware-led revenue mix is expected to limit gross-margin expansion, while services recovery should remain gradual.
Competition across networking and security still requires sustained product execution. Acquisition exposure and an elevated valuation leave less room for disappointment. The balanced mix of durable growth drivers and execution, margin and valuation risks supports the Neutral recommendation.
(You can read the full research report on Cisco here >>>)
Shares of Lam Research have outperformed the Zacks Electronics - Semiconductors industry over the past year (+123.1% vs. +27.4%). The company is benefiting from AI-driven investment in memory, leading-edge foundry and advanced packaging. Rising process complexity is increasing demand for etch and deposition tools, while NAND conversions, advanced DRAM and larger packages expand its served market.
Customer Support is scaling through upgrades, high utilization and early adoption of Equipment Intelligence and Dextro services. Record fiscal 2026 results, higher margin targets and a sizable September-quarter outlook reinforce execution. Cash generation and capital returns add support.
However, equipment spending remains cyclical, China exposure is volatile, and export controls can disrupt demand. Competition, capacity limits and international exposure also remain risks. Overall, structural AI demand and rising technology content support the Outperform view.
(You can read the full research report on Lam Research here >>>)
Thermo Fisher’s shares have outperformed the Zacks Medical - Instruments industry over the past year (+36.2% vs. -0.5%). The company is gaining from improving customer activity across all end markets, continued share gains and disciplined execution of its growth strategy. Pharma and biotech demand is advancing, led by bioproduction, clinical research and the research and safety channel.
Clario and the filtration and separation business are bolstering the company’s capabilities and supporting revenue synergies. New products, AI-enabled workflows and expanded customer collaboration centers reinforce its competitive position.
Management raised its 2026 revenue and adjusted EPS outlook after better-than-expected second-quarter results. The Zacks Consensus Estimate projects 2026 EPS of $25.12 on revenues of $47.80 billion. Still, macroeconomic uncertainty, currency volatility, acquisition-related leverage and intense competition remain key risks.
(You can read the full research report on Thermo Fisher here >>>)
Shares of Ampco-Pittsburgh have outperformed the Zacks Metal Products - Procurement and Fabrication industry over the past year (+211.6% vs. +5.9%). This microcap company with a market capitalization of $160.93 million sees its outlook supported by ALP’s exposure to nuclear power, defense, power generation and mission-critical HVAC, alongside improving FCEP profitability after footprint optimization.
Stronger backlog, protective tariffs, improving FEP activity and better utilization in Sweden provide support for longer-term earnings and margin expansion. However, execution remains important as FCEP is exposed to steel-market cyclicality, product mix and utilization trends, while ALP must convert a growing backlog as capacity expands.
Elevated leverage, weak cash conversion, working-capital needs and asbestos obligations constrain financial flexibility. Residual U.K. recovery uncertainty also remains a risk. Valuation suggests limited near-term upside, making sustained earnings growth, margin expansion and deleveraging important catalysts for improving investor returns.
(You can read the full research report on Ampco-Pittsburgh here >>>)
Catalyst Bancorp’s shares have outperformed the Zacks Banks - Southeast industry over the past year (+36.2% vs. +10.9%). This microcap company with a market capitalization of $72.29 million, with its July 2026 Lakeside acquisition more than doubling its asset, loan and deposit base, is creating a larger franchise with greater earnings potential if the November systems conversion proceeds smoothly.
Funding trends are constructive, with deposits up 6% in the first half, lower deposit costs and a loan-to-deposit ratio of 82.9%. Credit quality also improved, as non-performing and past-due loans declined, supporting provision reversals. Net interest income rose 6.3% in the first half, aided by stronger securities income and growth in selected commercial categories.
However, challenges include 12.1% growth in non-interest expenses, a weaker efficiency ratio and a 4.4% decline in organic loans. Margin compression and heavy real estate exposure also raise sensitivity to funding costs and property-market conditions. Shares trade at 32.58X price/earnings, above peers
(You can read the full research report on Catalyst Bancorp here >>>)
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.